MSF hands over its DR-TB project to National TB Elimination Program in Mumbai

Médecins Sans Frontières (MSF)/Doctors Without Borders announced the planned closure of its Mumbai-based Drug-Resistant Tuberculosis (DR-TB) project by the end of 2024. This initiative has been providing comprehensive care to patients with complex cases of extensively drug-resistant TB (XDR-TB) since 2006. The project will be handed over to India’s National TB Elimination Program (NTEP) and the Brihanmumbai Municipal  Corporation (BMC), ensuring that the fight against TB in the region continues with sustainable support. 

In 2016, MSF partnered with NTEP to co-manage the DR-TB centre at Shatabdi Hospital, located in one of Mumbai’s high-burden areas, the M-East ward. This partnership has been instrumental in improving diagnosis, patient care, and treatment success rates. From the beginning of the collaboration, 7,431 DR-TB patients have been enrolled and treatment success rates have increased significantly, from 62 per cent to 80 per cent today. MSF’s contribution was key in pushing for and adopting the rapid deployment of newer diagnostic tools, individualised treatment plans, and patient-centric care, which was a major factor behind the success of this model. The work done at the Shatabdi Hospital was further supported by MSF’s community-level activities, which focused on raising awareness about TB and providing decentralised follow-up care for patients. 

Since its inception in 2006, MSF’s independent clinic in Mumbai played a critical role in treating the most complex cases of drug-resistant tuberculosis (DR-TB), providing care that was not available under the national protocols. The clinic enrolled a total of 828 patients, including 201 children and adolescents, many of whom were referred after failing previous DR-TB treatment regimens. MSF’s approach included the use of salvage regimens with newer drugs such as bedaquiline (BDQ) and delamanid (DLM), especially for younger patients who had few alternatives due to the toxicity, prolonged treatment durations, and poor tolerability of older drug regimens. 

These older treatments often led to severe side effects and lower success rates.  The clinic has been at the forefront of advancing DR-TB treatment, providing not only medical care but also psychosocial support and palliative care services. 

The knowledge and evidence generated through the project in Mumbai have had a global impact as well. MSF’s data contributed to the World Health Organization’s (WHO) 2020 guidelines on  DR-TB treatment, allowing the use of new drugs like BDQ and DLM together. These drugs, once available only through MSF, are now part of India’s national treatment program, which means patients will continue to have access to life-saving medication even after MSF’s clinic closes.  

MSF will continue to advocate for improved access to TB treatments, especially for children, and for shorter, all-oral regimens that are critical for patients with limited treatment options.